HOME >> MEDICINE >> NEWS
Pitt transplant researchers say anti-rejection drug rapamycin may help lupus, some cancers

PITTSBURGH, Jan. 22 Rapamycin, a drug approved for use in kidney transplant patients to prevent organ rejection, could also benefit patients with lupus and other autoimmune diseases as well as patients with blood cancers, such as acute myeloid leukemia, reports a team of researchers from the University of Pittsburgh's Thomas E. Starzl Transplantation Institute and Institute of Clinical Immunology and Transfusion Medicine, Justus-Liebig University in Giessen, Germany.

Their conclusions, outlined in a paper to be published in the journal Blood and currently posted on the journal's Web site (www.bloodjournal.org), were based on two key discoveries about rapamycin's mechanisms.

First, while rapamycin suppresses immune system T cells, as many anti-rejection drugs do, the researchers found that the drug also inhibits the function and activation of dendritic cells, cells that play a much earlier role in the immune response as the first cells to identify foreign intruders. They in turn present these intruders to other immune system cells, including T cells.

Second, and perhaps more surprising to the study's authors, rapamycin disarms the trigger that allows dendritic cells to proliferate. This trigger, a potent, naturally occurring growth factor, also affects the proliferation of blood precursor and stem cells, which if allowed to grow unchecked, result in leukemia and other cancers.

"Rapamycin's effect on dendritic cells impairs immune reactivity at the earliest stages. Because dendritic cells are important for the initiation and regulation of immune response, this effect is very important. Our findings provide novel insight into the pharmacology of this agent and have significant implications for the development of new therapeutic strategies in disease processes in which dendritic cells play a crucial immunopathological role," stated Angus W. Thomson, Ph.D., D.Sc., professor of surgery and immu
'"/>

Contact: Lisa Rossi
412-647-3555
University of Pittsburgh Medical Center
22-Jan-2003


Page: 1 2

Related medicine news :

1. Success of liver transplantation may be most influenced by three risk factors
2. Alcohol relapse adversely affects 10-year liver transplant survival
3. Donor age has no affect on long-term liver transplant survival
4. Age shouldnt be a factor in kidney transplantation
5. Cornea transplants can be improved
6. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
7. Hard choices: Pitt researcher presents findings on when to accept organ transplants
8. Biochemical marker aids prognosis in liver transplant patients
9. Single-donor islet transplantation procedure shows promise for patients with type 1 diabetes
10. Age should not be a factor in determining heart transplantation eligibility, researchers say
11. Study explores risks of obesity in children with kidney transplants

Post Your Comments:
(Date:9/4/2015)... ... , ... Mike Day, a former Navy SEAL who was shot 27 times ... in Kona on October 10th. , Mike is running the race to raise awareness ... the cutting-edge treatments that restore their quality of life. More than 300,000 ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... are prophetic details involving the Pope’s upcoming trip to the United States. , Yisrayl lays ... his role with the Vatican and society is. Yisrayl also provides the meaning of his ...
(Date:9/3/2015)... ... ... While bariatric surgeon Michael Feiz, M.D., F.A.C.S. notes that he advises all ... some patients have been recently asking further questions relating to the best way to ... surgery that should be followed in the days prior to the procedure, Dr. Feiz ...
(Date:9/3/2015)... ... 03, 2015 , ... The Oregon Collaborative for Integrative Medicine ... & Medicine (AIHM) Interprofessional Fellowship in Integrative Health & Medicine. The AIHM Fellowship ... renowned educator, physician and thought leader in integrative medicine. This is the first ...
Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3
(Date:9/4/2015)... LONDON , September 4, 2015 ... & Vaccines  Allergic Rhinitis drugs ... revenues Where is the market for allergic ... this market? Visiongain ,s new report shows you ... opportunities and prospects. Our 326 page report ...
(Date:9/4/2015)... Sep. 04, 2015 Research and ... "Investigation Report on China,s Sodium Ibandronate Market, 2010-2019" ... in the clinic under the trade name of Bondronat in ... in 1996, sodium ibandronate was approved by the FDA ... osteoporosis under the trade name of Boniva. However, since drug ...
(Date:9/4/2015)... , September 4, 2015 ... today announces that Hutchison MediPharma Limited ("HMP"), its ... in the second proof-of-concept ("POC") trial of fruquintinib ... cancer ("NSCLC") in China . ... succeeded in meeting the primary efficacy endpoint of ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
Cached News: